Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.
about
Update on the new 9-valent vaccine for human papillomavirus preventionSafety and Efficacy Data on Vaccines and Immunization to Human PapillomavirusCancer prevention as part of precision medicine: 'plenty to be done'Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsementEarly direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic reviewPopulation-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisCervical cancer prevention in Australia: Planning for the futureCharacterizing Twitter Discussions About HPV Vaccines Using Topic Modeling and Community DetectionMeasurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis.HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational studyThe case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in ScotlandThe impact of HPV vaccination on future cervical screening: a simulation study of two birth cohorts in Denmark.Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012.Cancers in Australia in 2010 attributable to infectious agentsQuality of physician communication about human papillomavirus vaccine: findings from a national survey.Determinants of geographic inequalities in HPV vaccination in the most populated region of France.Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girlsEffect of human papillomavirus vaccination on cervical cancer screening in Alberta.Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based studyDeclines in HPV-associated high-grade cervical lesions after introduction of HPV vaccines in Connecticut, US, 2008-2015.Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.Prophylactic HPV vaccination: past, present, and future.Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology.Potential impact of nonavalent HPV vaccine in the prevention of high-grade cervical lesions and cervical cancer in Portugal.Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study.Novel Approaches for Vaccination Against HPV-Induced Cancers.Tumour virus vaccines: hepatitis B virus and human papillomavirus.Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.Human Papilloma Virus Vaccination and Incidence of Ocular Surface Squamous Neoplasia.Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States.Parent Perception of Provider Interactions Influences HPV Vaccination Status of Adolescent Females.Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls.Strategies for evaluating the assumptions of the regression discontinuity design: a case study using a human papillomavirus vaccination programme.Recent trends of cervical cancer and Cervical Intraepithelial Neoplasia 3 (CIN3) in Israel.
P2860
Q26743630-94E6A5C9-7E75-4D39-A002-B0EEB925EC70Q26799574-4C1F5CA7-29F2-410D-AB65-4F65317E678BQ26995183-F1EAEDA9-4928-4448-8611-7FC42D7C3F3BQ28069669-1793E0A8-9460-49AF-B7A0-BBF16D3A0AC4Q28081927-D41ADD55-0F38-4F79-A52E-AA1FE97AE65CQ28084924-D0E0CCBB-F54B-4DBD-8CF7-780B47712727Q28270412-50300085-C7CD-458F-8D3B-608DC73BCB7FQ28595890-83FE30B4-96C8-4FF2-9ED8-D32EE51523A2Q33856453-2B273601-BDB5-44D7-B842-C06970A0590FQ34241823-B1C5CC83-9965-46C8-9207-3C0032C3635AQ34507291-983785AC-1743-4CEA-ABE3-879280663685Q34987731-54DBB320-411E-4049-B2BB-9DD9FB11D4B1Q35078557-26C746CF-5A61-44C5-B3AA-6AA7C5E1BA2BQ35678090-63E777AF-A26F-476F-B12A-A865D9D988D4Q35959884-0ED19FA0-9E5D-47BE-BBA4-06F42024E00AQ35997434-76AF04D1-57CA-4DDE-BF41-03FCFF4C3393Q36164438-AD165442-8289-4BE7-BF06-BF1A6D8058BCQ36249108-3C25D052-96B6-4E98-92AB-C63AB7044093Q36296590-7316C692-629B-4525-8717-FB6957AC744EQ37135074-C768AE90-05A7-46D7-BFA5-387178B4D36FQ37135276-CDD1EA94-2471-416E-8EC0-33635D080F6BQ37227066-EB41805D-A12D-40FC-877D-7052C949AB76Q37349077-0EEDFA17-B2C2-4F91-AEC0-DC8813E37971Q37834158-D723582D-B351-40A6-B3A4-E451CE6DCFBDQ38229304-2EB0461A-1F4D-4609-82A8-D6BBA6738486Q38586257-172AC821-EB56-4E6E-9BB4-73C719E072E0Q38597567-A808A898-91D5-4697-934C-3A8A2E3C6E01Q38673879-F870003A-C0C1-4D5E-B6F8-205927537D3AQ38717156-CB249773-A63C-4376-913A-A09EF2F024BDQ38733067-9A80DD1F-6DA3-4D3D-ADAF-9FF35EF741C1Q39012586-60A59094-84E9-4702-9D67-C2238699DB4FQ39033362-DCD3215E-EA0D-4B9F-93E3-CF9F73C12D74Q40046649-63CB6E80-1750-4667-82D5-55B97F80CE6EQ40168801-461E9132-889A-4E32-BD37-4E66A15B7F4DQ40451271-33267C85-F7D9-4E58-A3C7-6B15E7188A7DQ40812471-843C252D-4EFD-4174-B4E8-731072B99317Q40960115-CFE22D10-C860-4A35-9F53-502DCED04210Q40973012-D8310BE1-8586-4898-BDB2-624BE0F4BBA0Q41010064-8C7F952B-1FC6-4C47-8C87-D75EBB3E6AC8Q41412453-CFA3CC46-53E9-476C-96D8-053384D99E9C
P2860
Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effectiveness of quadrivalent ...... eening programme in Australia.
@en
Effectiveness of quadrivalent ...... eening programme in Australia.
@nl
type
label
Effectiveness of quadrivalent ...... eening programme in Australia.
@en
Effectiveness of quadrivalent ...... eening programme in Australia.
@nl
prefLabel
Effectiveness of quadrivalent ...... eening programme in Australia.
@en
Effectiveness of quadrivalent ...... eening programme in Australia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Effectiveness of quadrivalent ...... reening programme in Australia
@en
P2093
Annette J Dobson
Elizabeth Crowe
Julia M L Brotherton
P2860
P356
10.1136/BMJ.G1458
P407
P577
2014-03-04T00:00:00Z